| Biotechnology Industry | Healthcare Sector | Ms. Victoire Viannay CEO | XMUN Exchange | - ISIN |
| Sweden Country | 11 Employees | - Last Dividend | 26 Mar 2025 Last Split | - IPO Date |
Fluicell AB (publ) is a pioneering life science company based in Mölndal, Sweden, established in 2012. The company specializes in providing innovative platforms and research solutions primarily focused on bioprinting and single-cell biology. These cutting-edge technologies are designed to enhance the precision and control in various biological research applications, including drug discovery, cell biology, and tissue engineering. Fluicell is committed to advancing scientific research by offering tools that enable researchers to manipulate and analyze single cells and complex biological systems with unprecedented accuracy and efficiency.
A microfluidic platform tailored for high-precision delivery of solutions to individual cells, allowing for the manipulation of the cell microenvironment. This technology is crucial for experiments requiring precise control over the conditions affecting cells, without the need to physically disturb the cells. It offers an innovative way to study cell behavior under various conditions
This platform is designed to facilitate the generation of dose-response curves or the study of multiple drug compounds on cells. It offers a unique approach to examining the effects of different chemical compounds on cells in a controlled and systematic manner, making it invaluable for drug development and toxicology studies.
A cutting-edge ion channel screening platform that enables researchers to record various ion channel currents in a patch-clamp recording configuration. This technology is particularly useful for pharmacological research, where understanding ion channel behavior is crucial for the development of new drugs and therapies.
A 3D single-cell bioprinting platform that ensures high cell viability and promotes cell-to-cell communication. This technology represents a significant advancement in tissue engineering and regenerative medicine, as it allows for the precise placement of cells in three-dimensional structures to mimic natural tissue architectures.
An accessible 3D bioprinting platform designed to fit within fume hoods or biosafety cabinets, making it more convenient for research laboratories. This version of Biopixlar emphasizes user-friendliness and safety, allowing for the creation of complex tissue constructs under contained conditions.
In addition to these innovative platforms, Fluicell also provides a wide range of accessory and consumable products aimed at facilitating research in bioprinting and single-cell biology.